{
  "created_at": "Mon Aug 16 18:53:56 +0000 2021",
  "id_str": "1427336933882089477",
  "full_text": "Pfizer and BioNTech began the formal process of seeking FDA clearance for a Covid-19 booster shot, submitting data showing a third vaccine dose generated higher levels of neutralizing antibodies against the original virus and its Beta and Delta variants https://t.co/BPUycg9PZw",
  "display_text_range": [
    0,
    277
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/BPUycg9PZw",
        "expanded_url": "https://on.wsj.com/3xV228u",
        "display_url": "on.wsj.com/3xV228u",
        "indices": [
          254,
          277
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 36,
  "favorite_count": 108,
  "possibly_sensitive": false,
  "original_created_at": "Mon Aug 16 18:30:18 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "ファイザー社とバイオンテック社は、Covid-19のブースターショットについて、FDA（米国食品医薬品局）の認可を得るための正式な手続きを開始し、3回目のワクチン投与により、オリジナルのウイルスとそのベータおよびデルタ変異体に対して、より高いレベルの中和抗体が生成されたというデータを提出した。https://t.co/BPUycg9PZw"
    },
    {
      "locale": "zh",
      "full_text": "辉瑞公司和BioNTech公司开始为Covid-19加强针寻求FDA许可的正式程序，提交的数据显示第三剂疫苗产生了更高水平的针对原始病毒及其Beta和Delta变体的中和抗体https://t.co/BPUycg9PZw。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "輝瑞公司和BioNTech公司開始爲Covid-19加強針尋求FDA許可的正式程序，提交的數據顯示第三劑疫苗產生了更高水平的針對原始病毒及其Beta和Delta變體的中和抗體https://t.co/BPUycg9PZw。"
    }
  ]
}